Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 2/20 | 0.53 |
| ▸ | BCHE | P06276 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
| ▸ | BACE1 | P56817 | 2/20 | 0.47 |
| ▸ | PHGDH | O43175 | 1/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2804476 | 0.89 | TEAD1 (0.56) | TEAD1BCHEACHEBACE1PHGDH | |
| SCHEMBL3631495 | 0.89 | TEAD1 (0.52) | TEAD1BCHEACHEBACE1PHGDH | |
| SCHEMBL14216185 | 0.89 | ACHE (0.45) | TEAD1BCHEACHEBACE1DRD4 | |
| SCHEMBL2808223 | 0.88 | BCHE (0.51) | TEAD1BCHEACHEBACE1EPHX2 | |
| SCHEMBL2802531 | 0.88 | TEAD1 (0.54) | TEAD1BCHEACHEBACE1PHGDH | |
| SCHEMBL2802000 | 0.87 | TEAD1 (0.53) | TEAD1BCHEACHEBACE1PHGDH | |
| SCHEMBL3629314 | 0.85 | TEAD1 (0.58) | TEAD1BCHEACHEBACE1PHGDH | |
| SCHEMBL4861074 | 0.82 | PTPN1 (0.37) | SLC6A5DRD2DRD4CYP3A4MAPT | |
| SCHEMBL4569598 | 0.78 | TEAD1 (0.53) | TEAD1BCHEACHEBACE1PHGDH | |
| SCHEMBL3457225 | 0.78 | TEAD1 (0.61) | TEAD1BCHEACHEBACE1PHGDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150297597-A1 | METHODS OF TREATMENT OF SKIN ULCERS | UNIV PENNSYLVANIA (US) | 2015-10-22 | — | — | US | disclosed |
| EP-2155225-B1 | METHODS OF TREATMENT OF SKIN ULCERS | UNIV PENNSYLVANIA (US) | 2015-07-08 | — | — | EP | disclosed |
| US-20150183748-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | THOMAS JEFFERSON UNIVERSITY | 2015-07-02 | — | — | US | disclosed |
| US-9029383-B2 | Methods of treatment of skin ulcers | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-05-12 | — | — | US | disclosed |
| EP-2152865-B1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | UNIV JEFFERSON (US) | 2015-04-15 | — | — | EP | disclosed |
| US-8962633-B2 | Methods of treatment and prevention of metabolic bone diseases and disorders | THOMAS JEFFERSON UNIVERSITY (US) | 2015-02-24 | — | — | US | disclosed |
| US-20130150379-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2013-06-13 | — | — | US | disclosed |
| US-20100239565-A1 | METHODS OF TREATMENT OF SKIN ULCERS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2010-09-23 | — | — | US | disclosed |
| EP-2155225-A1 | METHODS OF TREATMENT OF SKIN ULCERS | The Trustees of the University of Pennsylvania (US) | 2010-02-24 | — | — | EP | disclosed |
| EP-2083625-A2 | BICYCLIC HETEROAROMATIC COMPOUNDS | Glaxo Group Limited (GB) | 2009-08-05 | — | — | EP | disclosed |
| US-20080103156-A1 | Bicyclic Heteroaromatic Compounds | GLAXO GROUP LIMITED (GB) | 2008-05-01 | — | — | US | disclosed |
| US-20080103156-A1 | Bicyclic Heteroaromatic Compounds | GLAXO GROUP LIMITED (GB) | 2008-05-01 | — | — | US | disclosed |
| WO-2008048867-A2 | BICYCLIC HETEROAROMATIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-04-24 | — | — | WO | disclosed |
| WO-2008048867-A2 | BICYCLIC HETEROAROMATIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-04-24 | — | — | WO | disclosed |
| US-20080090851-A1 | Bicyclic Heteroaromatic Compounds | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | US | disclosed |
| US-20080090851-A1 | Bicyclic Heteroaromatic Compounds | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | US | disclosed |
| US-20080090851-A1 | Bicyclic Heteroaromatic Compounds | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | US | disclosed |
| US-20080090852-A1 | Bicyclic Heteroaromatic Compounds | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | US | disclosed |
| US-20080090852-A1 | Bicyclic Heteroaromatic Compounds | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | US | disclosed |
| US-20080090852-A1 | Bicyclic Heteroaromatic Compounds | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090851-A1 | Bicyclic Heteroaromatic Compounds | CYP11B1, CYP46A1, CYP11B2 | TEAD1 657/4885BCHE 2441/4885ACHE 3983/4885 |
| US-20150297597-A1 | METHODS OF TREATMENT OF SKIN ULCERS | PLA2G12A, PLA2G3, PLA2G4A | TEAD1 4492/4885BCHE 2845/4885ACHE 1384/4885 |
| US-20080090852-A1 | Bicyclic Heteroaromatic Compounds | CYP11B1, CYP46A1, CYP11B2 | TEAD1 639/4885BCHE 2544/4885ACHE 4187/4885 |
| US-20130150379-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | LPL, PLA2G1B, PLA2G2A | TEAD1 3794/4885BCHE 76/4885ACHE 34/4885 |
| US-20100239565-A1 | METHODS OF TREATMENT OF SKIN ULCERS | PLA2G12A, PLA2G3, PLA2G4A | TEAD1 4492/4885BCHE 2845/4885ACHE 1384/4885 |
| US-20150183748-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | LPL, LPAR1, PLA2G1B | TEAD1 4185/4885BCHE 53/4885ACHE 31/4885 |
| US-20080103156-A1 | Bicyclic Heteroaromatic Compounds | CYP11B1, CYP46A1, CYP11B2 | TEAD1 657/4885BCHE 2441/4885ACHE 3983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.